Piotr Mroczko
Piotr Mroczko
Research assistant, University of Białystok
Zweryfikowany adres z uwb.edu.pl
Tytuł
Cytowane przez
Cytowane przez
Rok
Clinical significance of fluid biomarkers in Alzheimer’s disease
P Lewczuk, M Łukaszewicz-Zając, P Mroczko, J Kornhuber
Pharmacological Reports 72 (3), 528-542, 2020
82020
CXCL-8 in Preoperative Colorectal Cancer Patients: Significance for Diagnosis and Cancer Progression
S Pączek, M Łukaszewicz-Zając, M Gryko, P Mroczko, ...
International Journal of Molecular Sciences 21 (6), 2040, 2020
72020
Consent to medical procedures of patients with neurodegenerative diseases: a comparative study of legal regulations in selected European countries and in the United States
EM Guzik-Makaruk, EW Pływaczewski, P Mroczko, M Olesiuk-Okomska, ...
Journal of Alzheimer's Disease 63 (1), 53-67, 2018
72018
Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia
A Kulczyńska-Przybik, A Słowik, P Mroczko, B Borawski, M Groblewska, ...
Current Alzheimer Research 17 (8), 709-721, 2020
52020
The Significance of CXCL1 and CXCL8 as Well as Their Specific Receptors in Colorectal Cancer
M Łukaszewicz-Zając, S Pączek, P Mroczko, A Kulczyńska-Przybik
Cancer Management and Research 12, 8435, 2020
52020
A comparative analysis of the treatment of decision-making by or for patients with neurodegenerative diseases in four legal jurisdictions
EM Guzik-Makaruk, EW Pływaczewski, K Laskowska, W Filipkowski, ...
Journal of Alzheimer's Disease 70 (1), 1-10, 2019
52019
The Implication of Reticulons (RTNs) in Neurodegenerative Diseases: From Molecular Mechanisms to Potential Diagnostic and Therapeutic Approaches
A Kulczyńska-Przybik, P Mroczko, M Dulewicz, B Mroczko
International Journal of Molecular Sciences 22 (9), 4630, 2021
2021
The legal capacity of patients with Alzheimer's disease: Supportive and therapeutic environments
P Mroczko
Alzheimer's & Dementia 16, e043641, 2020
2020
The cerebrospinal fluid fractalkine as a biomarker in mild cognitive impairment (MCI) Biomarkers (non‐neuroimaging)/novel biomarkers
B Mroczko, A Kulczynska‐Przybik, A Klimkowicz‐Mrowiec, J Pera, ...
Alzheimer's & Dementia 16, e039731, 2020
2020
The legal capacity of patients with Alzheimer's disease
P Mroczko
2020 Alzheimer's Association International Conference, 2020
2020
The cerebrospinal fluid fractalkine as a biomarker in mild cognitive impairment (MCI)
B Mroczko, A Kulczynska-Przybik, A Klimkowicz-Mrowiec, J Pera, ...
2020 Alzheimer's Association International Conference, 2020
2020
P3‐512: MEDICAL DOCTORS’AWARENESS CONCERNING LEGAL PROBLEMS RELATED TO DEALING WITH PATIENTS WITH ALZHEIMER'S DISEASE
EM Guzik-Makaruk, EW Pływaczewski, P Mroczko
Alzheimer's & Dementia 14 (7S_Part_24), P1318-P1318, 2018
2018
P4‐184: SOCIAL EXCLUSION OF PATIENTS WITH ALZHEIMER'S DISEASE
EM Guzik-Makaruk, EW Pływaczewski, P Mroczko
Alzheimer's & Dementia 14 (7S_Part_29), P1509-P1509, 2018
2018
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–13